Table 3.
Clinical response to bevacizumab treatment
| Patient | Change in daily steroid dose (mg) | Symptomatic response | Reason for discontinuation |
|---|---|---|---|
| 1 | 8–> 0 | Worsened | No symptomatic response |
| 2 | 2–> 0.3 | Improved | Good response |
| 3 | 4–> 0 | Improved* | Good response |
| 4 | 0.2–> 0 | Stable | No symptomatic response |
| 5 | – | Improved | Good response |
| 6 | – | Improved | Current |
| 7 | 24–> 0 | Stable | No symptomatic response |
| 8 | 20–> 0 | Improved | Good response |
| 9 | 6–> 0 | Improved | Good response |
| 10 | 8–> 2 | Improved | Current |
| 11 | 8–> 0 | Stable | Current |
*Patient also treated with anti-epileptic, potentially contributing to response.